A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with …
Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting
its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to …
its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to …
Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect
W Chen, B Jiang, Z Ruan, D Yang, Y Hu… - BMC Pharmacology and …, 2024 - Springer
Febuxostat is commonly used in clinic for the treatment of hyperuricemia. Multiple-peak
phenomenon has been observed in human plasma concentration-time profiles of febuxostat …
phenomenon has been observed in human plasma concentration-time profiles of febuxostat …
[HTML][HTML] Up-To-Date Perspectives for Hyperuricemia, Cardiorenal Influence and Urate-Lowering Therapy (ULT)
H Bando - Diabetes Research: Open Access, 2021 - asploro.com
Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest
topics are described. The guideline adequately managing gout was published from …
topics are described. The guideline adequately managing gout was published from …
[图书][B] Mixed Effects Modeling of Deterministic and Stochastic Dynamical Systems-Methods and Applications in Drug Development
J Leander - 2021 - search.proquest.com
Mathematical models based on ordinary differential equations (ODEs) are commonly used
for describing the evolution of a system over time. In drug development, pharmacokinetic …
for describing the evolution of a system over time. In drug development, pharmacokinetic …